IMPORTANCE Medication nonadherence accounts for up to half of uncontrolled hypertension. Smartphone applications (apps) that aim to improve adherence are widely available but have not been rigorously evaluated.
H ypertension is estimated to affect 34% of US adults 20 years or older, accounting for more than 73 000 deaths each year.
1 Among modifiable risk factors, eliminating uncontrolled hypertension is estimated to have the single greatest potential to reduce cardiovascular mortality in women, and to have an effect that is second only to smoking cessation in men. 1 While many factors contribute to poorly controlled hypertension, nonadherence is thought to account for nearly half of all such cases. 2, 3 In fact, among patients classified as having "medication-resistant" hypertension, more than 50% are actually nonadherent to their prescribed medications.
3
Mobile health (mHealth) interventions, such as smartphone applications (apps), have been advocated as promising strategies to assist in the self-management of hypertension 4, 5 and other chronic conditions. 6 These tools have the potential to address nonadherence by providing reminders for medication taking and refilling, tracking biometric results, offering education, and facilitating social interactions that provide support and motivation. 7 From 2012 to 2015 there was a 515% increase in adherence apps available for download, 8 and there are an estimated 107 apps currently available for hypertension alone.
9
While the existing literature demonstrates improvements in blood pressure from smartphone technology, 5, [10] [11] [12] these studies have been conducted in clinic-based settings and have mainly tested the use of mHealth strategies that aim to improve communication between patients and physicians in the context of established therapeutic relationships. In contrast, a 2015 survey found that only 20% of smartphone health app users had received a recommendation by a physician to download an app 13 and that most patients download and use apps without the active participation of their physician. Accordingly, we sought to evaluate the association of medication adherence and blood pressure control with a "stand-alone" smartphone app among patients with poorly controlled hypertension.
Methods

Study Design
The Medication adherence Improvement Support App For Engagement-Blood Pressure (MedISAFE-BP) Trial was a randomized clinical trial of individuals with uncontrolled hypertension in the United States. Enrollment began on April 25, 2016, and was completed on September 16, 2016. The full details of the trial design have been published previously, 14 and the study has been registered on clinicaltrials.gov (NCT02727543). See the Trial Protocol in Supplement 1. The trial was reviewed and approved by the Chesapeake institutional review board, and all patients provided written informed consent prior to enrollment. All participants were provided compensation of up to $150 for their time to participate in the study. The academic authors were responsible for scientific oversight, including the design of the protocol. Patient recruitment, screening, randomization, follow-up, and data management were performed by Evidation Health without any involvement from the study sponsor. The academic authors used an independent copy of the study database to analyze the results and vouch for their analytic accuracy and completeness as well as the fidelity of the report to the study protocol.
Participants
We included individuals ages 18 to 75 years with a systolic blood pressure of 140 mm Hg or greater receiving treatment with at least 1, but no more than 3, first-line antihypertensive medications (thiazide, calcium channel blocker, β-blocker, angiotensin-converting enzyme inhibitor, or angiotensin receptor blocker). To identify participants with uncomplicated essential hypertension, we excluded patients prescribed 4 or more antihypertensive medications, those on dialysis, or those whose blood pressure was greater than 180/120 mm Hg on home blood pressure confirmation (see the Patient Recruitment and Randomization subsection for additional details). We also excluded individuals receiving chemotherapy at the time of screening as well as patients who were unable to understand written English, did not have a smartphone with compatible operating system (iOS or Android), were already using a smartphone medication adherence app, or did not live in the United States with a valid mailing address.
Patient Recruitment and Randomization
Participants were recruited through online patient communities, social media, pertinent mobile apps, and targeted advertisements. 14 Potential participants were directed to a study website to assess eligibility and to provide informed consent. Eligible participants completed a baseline survey consisting of demographics and cardiovascular comorbidities, the 8-item Morisky medication adherence scale , 15 the hypertension knowledge questionnaire, 16 and the Consumer Health Activation Index to assess patient activation (Michael Wolf, PhD, email communication, November 25, 2015) . The MMAS is a widely used tool for selfreported medication adherence that was found to be reliable (α = .83), significantly associated with blood pressure control (P < .05), and to have 93% sensitivity as well as 53% specificity for low adherence in a validation study.
15
Key Points
Question Does use of a smartphone application (app) improve self-reported adherence to antihypertensive medications and blood pressure control?
Findings In this randomized clinical trial of 411 adults with poorly controlled hypertension, patients randomized to receive a smartphone app had a small improvement in self-reported medication adherence with no difference in blood pressure compared with controls.
Meaning Use of a smartphone app resulted in a small improvement in self-reported medication adherence but did not affect blood pressure; the benefit of this and other stand-alone mobile health interventions on clinical outcomes remains to be established.
Potentially eligible individuals were then mailed a Bluetooth-enabled blood pressure monitor (UA-651 BLE; A & D Medical) as well as instructions on how to set up the monitor and properly take a blood pressure reading. TheA&D651 blood pressure cuff has been approved by blood pressure associations for its accuracy in home use.
17 Study participants were asked to provide 2 measurements that were taken 5 minutes apart, in accordance with professional society guidelines, 18 and blood pressure was calculated as the average of these measurements. Patients were instructed to perform all blood pressure measurements in a seated position and at least 30 minutes after smoking, eating, drinking caffeinated drinks, or physical activity. Because of the pragmatic nature of this study, acceptable readings were considered to be 2 measurements that were at least 3 minutes apart but not more than 30 minutes apart. If, on this assessment, an individual's average systolic blood pressure was confirmed to be greater than 140 mm Hg, but also less than 180/120 mm Hg, they were enrolled and randomized in a ratio of 1:1 to the intervention or control through the online portal using a random number generator. Study participants and study staff interacting with patients were not blinded to group assignment. The study investigators and data analysts remained blinded until all follow-up data were obtained and the primary analytic strategies were finalized.
Intervention
Participants randomized to the intervention arm were provided with instructions on how to download and use the Medisafe app. This app aims to help individuals adhere to their prescribed therapies and has received the highest usability rating among medication adherence smartphone apps in several reviews. 8, 19 There are several key features of the app. First, medication lists are entered manually, along with their preferred timing of administration, or are autopopulated through a linkage with an existing medication record. In those cases in which this integration has been established, the app provides alerts to remind patients when it is time for them to take medications and generates weekly adherence reports. Second, the app also allows for tracking of blood pressure and other biometric measurements, although in the current study, the Medisafe app did not automatically sync with the home blood pressure cuff or interface with medical professionals in any way. Finally, users can designate a "Medfriend" who is granted access to the patient's medication taking history, receives alerts when doses are missed, and can provide peer support. Intervention arm participants who did not download the app and have 1 login within 2 days of randomization were contacted by email and telephone.
14 If, after multiple follow-up attempts, a participant still did not log in, they were not contacted further but were followed for outcomes and analyzed in the intent-to-treat analysis. The control arm did not receive any intervention.
Follow-up Assessment
Follow-up assessments were performed for participants in both study arms at 4, 8, and 12 weeks after enrollment based on intention-to-treat principles. As such, outcomes were evaluated in all randomized individuals, including those in the intervention arm who did not download the app. Each assessment included blood pressure measurement using the studyprovided blood pressure monitor. 18 The final study assessment at 12 weeks also included an exit survey that measured adherence, hypertension knowledge, and patient activation.
Outcomes
The co-primary outcomes were change in self-reported medication adherence and systolic blood pressure from randomization to 12 weeks. The secondary outcome was whether participants had well-controlled blood pressure, defined as 140/90 mm Hg or less.
20
Statistical Analysis
We sought to enroll at least 390 patients to have 80% power to detect a 5-mm Hg difference in systolic blood pressure between treatment arms, with an α of .05, even with a 20% loss to follow up or a standard deviation of up to 17 mm Hg. A decrease in systolic blood pressure by 5 mm Hg correlates with clinically meaningful reductions in coronary heart disease and stroke. [21] [22] [23] This sample size also provided 87% power to detect a 0.5-point difference in adherence between the groups assuming a standard deviation of 1.6, 15 a similar loss to follow-up, and an α of .05. We conducted our analyses using intention-to-treat principles. Means and frequencies of baseline characteristics were evaluated for any between-arm differences despite randomization. As prespecified in the published protocol, 14 the co-primary outcomes were analyzed using univariate linear regression models, and missing data were accounted for using multiple imputation with PROC MI using SAS statistical software (version 9.4; SAS Institute Inc), after the creation of 25 imputed data sets. 24, 25 The secondary outcome was analyzed using univariate logistic regression. We defined statistical significance as P < .05 and we did not adjust our P value threshold for our 2 co-primary outcomes, which we assumed would be correlated. [26] [27] [28] In secondary analyses, we fitted multivariable models to adjust for the following baseline characteristics that have been associated with medication adherence and/or blood pressure control: sex, race/ethnicity, body mass index (BMI, calculated as weight in kilograms divided by height in meters squared), physical activity, education, cigarette use, patient activation, and baseline adherence. In sensitivity analyses, we repeated our analyses among those individuals for whom complete outcome data were available. We also evaluated longitudinal changes in blood pressure measurements at baseline and each of the subsequent 3 follow-up assessments using generalized estimating equations with an identity link function and autoregressive errors.
In subgroup analyses, we evaluated differential effects of the intervention on the co-primary outcomes with respect to sex, age, baseline blood pressure, baseline adherence, and baseline patient activation based on the statistical significance of the interaction term for the subgroup of interest in the multivariable model. Finally, adherence was analyzed with respect to movement between adherence categories based on the MMAS-8 score, which is how this scale was originally described. 15 In specific, an MMAS-8 score of less than 6 was classified as "low" adherence, 6 or 7 was classified as "moderate" adherence, and 8 was classified as "high" adherence. All analyses were performed using SAS software (version 9.4).
Results
Participants
We screened 5577 individuals, of whom 1160 met eligibility criteria and provided a home blood pressure measurement ( Figure 1) . A total of 412 participants with poorly controlled blood pressure were randomized, 210 to the intervention arm and 202 to the control arm. One person withdrew from the intervention arm. Therefore, the intention-to-treat analysis included 209 patients in the intervention arm and 202 controls.
Baseline Characteristics
Participants were located across the United States in a mix of rural, suburban, and urban locations. Participants had a mean age of 52.0 years and a mean BMI of 35.5; 247 (60%) were female, and 103 (25%) were of black race/ethnicity. The baseline characteristics of the intervention arm were generally similar to those of the controls (Table 1) . Sex, race/ethnicity, BMI, and baseline adherence were well balanced between the 2 arms. Intervention participants were more likely than controls to report being white (71.3% compared with 58.9%; P = .03), currently use cigarettes (18.7% compared with 10.9%; P = .03), and to have dyslipidemia (48.8% compared with 36.6%; P = .01). Among the intervention arm, 188 (90%) downloaded and launched the smartphone app.
Medication Adherence
At baseline, mean (SD) adherence as measured by the MMAS-8 was 6.0 (1.8) among the intervention arm and 5.7 (1.8) among controls. By 12 weeks of follow-up, the mean (SD) adherence increased by 0.4 (1.5) in the intervention arm and remained unchanged among controls (between-group difference, 0.4; 95% CI, 0.1-0.7; P = .01) ( Table 2 ). The results remained unchanged after adjustment for differences in baseline characteristics in secondary analyses and in the complete case analysis (eTable in Supplement 2). Subgroup analyses of the association of the intervention with adherence by sex, age, baseline systolic blood pressure, baseline adherence, and activation showed no significant between-group differences, although the magnitude of the improvement in adherence was largest for participants reporting low baseline adherence ( Table 3) . Consistent with this, the overall improvement in adherence from the intervention resulted from a reduction in the proportion of patients with low levels of adherence and a commensurate rise in the proportion of individuals with moderate adherence (Figure 2) . a These subgroup analyses were conducted after multiple imputation and without any adjustment for baseline characteristics. The presented numbers reflect the difference between intervention and control groups in outcomes from baseline to 12 weeks. As a result, positive numbers reflect differences that were larger among intervention group than controls and negative numbers reflect differences that were smaller among the intervention group than controls.
b Adherence was measured by the 8-item Morisky Medication Adherence Scale. 
Blood Pressure
At baseline, the mean (SD) systolic blood pressure was 151.4 (9.0) mm Hg in the intervention arm and 151.3 (9.4) mm Hg among controls. After 12 weeks of follow-up, the mean (SD) systolic blood pressure decreased by 10.6 (16.0) mm Hg in the intervention group and by 10.1 (15.4) mm Hg in the control group (Table 2) . There was no difference in the change in blood pressure between the groups (between-group difference, 0.5 mm Hg; 95% CI, −3.7 to 2.7 mm Hg; P = .78). Good blood pressure control (defined as blood pressure <140/90 mm Hg) at 12 weeks was achieved by 35.8% in the intervention group and 37.9% in the control group (odds ratio, 0.9; 95% CI, 0.6-1.4; P = .68). Analyses of the 2 blood pressure outcomes remained unchanged after multivariable adjustment in secondary analyses and in complete case analysis (see eTable in Supplement 2). Changes in blood pressure over time are shown in the eFigure in Supplement 2. A longitudinal model of blood pressure over time had an effect estimate of -0.5 mm Hg per month (95% CI, −3.2 to 2.1mmHg;P = .70). Subgroup analyses of the association of the intervention with systolic blood pressure by sex, age, baseline systolic blood pressure, baseline adherence, and patient activation showed no significant between-group differences (Table 3) .
Discussion
Among those with poorly controlled hypertension, patients randomized to the use of a stand-alone smartphone app had a small improvement in self-reported medication adherence but no change in systolic blood pressure at 12 weeks of follow-up compared with controls.
There are several potential explanations for finding a small improvement in self-reported medication adherence without corresponding reductions in blood pressure. Readings from home blood pressure monitoring devices were used to determine trial eligibility and evaluate outcomes. It is possible that the reductions in blood pressure from baseline to the end of follow-up that we observed in both the intervention and control arms may have resulted from fluctuations in these home blood pressure readings 29 and/or regression to the mean, and that the magnitude of these changes was larger than the a priori hypothesized effect from the smartphone app. Furthermore, patients in both arms were required to submit home blood pressure readings periodically, which was done a median of 10 and 9 times by the intervention and control groups, respectively, over the 12 weeks of study follow-up. Thus, all patients were engaged in some level of self-monitoring. This has shown to have small positive effects on blood pressure control 30 and medication adherence 31 and may have been particularly motivating for the participants in our trial, who were a relatively small proportion of those who underwent initial screening for inclusion. Alternatively, while we observed a statistically significant improvement in adherence from the intervention, the magnitude of this change was likely too small to translate into improvements in blood pressure. A change of 2 points in the MMAS-8 has been suggested as the minimum detectable difference for antihypertensive medication adherence, 32 which is substantially larger than the mean 0.4-point change that we observed. Similarly, it seems that patients must be highly adherent to their prescribed antihypertensive medications to derive clinical benefit. 33, 34 In contrast, the improvement in adherence that we observed resulted primarily from patients with low levels of adherence at baseline becoming moderately adherent by the end of follow-up, with little difference between intervention and controls in the proportion of patients who were highly adherent. If becoming highly adherent from the intervention takes more time than the 12-week duration of our trial, it is possible that we would have observed larger adherence improvements and corresponding changes in blood pressure with longer follow-up. Finally, medication adherence was measured by self-report. While the tool we used has been validated and extensively used, 15 self-reported questionnaires are subject to social desirability bias and may overestimate true adherence. 35 As such, after exposure to an app that very clearly encouraged adherence, intervention arm participants may have been more likely to report being adherent without actually changing their medication-taking behavior. How then could use of a smartphone app be enhanced to result in greater benefits for patients with hypertension? While the app we tested has received very high usability scores, 8, 19 it may be that individuals with hypertension have needs that are different from those of individuals with other conditions. Therefore, one solution is to offer more diseasespecific customization of smartphone tools. An alternative idea is to link the app to clinical care. Several studies have shown greater effects on clinical outcomes when home selfmonitoring of blood pressure is linked with additional support, mostly through connection to health care professionals. 30, 36 In keeping with this, prior trials of text messaging for individuals with hypertension had positive results compared with control. 10, 37 In these trials, participants were enrolled from a clinical setting, and therefore patients likely associated the messages they received with their primary care physicians, potentially leading to greater effect. Similarly, the only randomized clinical trial of an mHealth app for patients with hypertension relied heavily on nurse health coaches to provide treatment recommendations. 12 In that study, Moore et al 12 evaluated the use of CollaboRhythm, an interface that allows tracking of medications and pairs a patient with a coach to offer recommendations and reminders. After 12 weeks, those in the intervention arm decreased their blood pressure by 10 mm Hg more than the control group. It is important to note, however, that using apps in the context of clinical care and relying on physicians to interact with patients for them to work is resource intensive and undercuts the efficiencies of stand-alone tools to aid patients in self-management.
Limitations
There are several limitations of this trial. Recruitment was performed entirely using online mechanisms. While it is estimated that more than 50% of patients use the internet for medical information, 38 the results of our trial may not be generalizable to other populations of individuals with poorly controlled hypertension, who may have different sociodemographic and comorbidity characteristics than the patients in our study participants. Furthermore, because home blood pressure measurements tend to be lower than those obtained by health care professionals, 39 our study population may, in fact, have had less well-controlled hypertension than patients for whom the same inclusion criteria had been applied in an office-based setting. In addition, we excluded those with extremely high blood pressure, for which immediate medical attention is recommended, and therefore this intervention may not be applicable to populations with blood pressures greater than 180/120 mm Hg. Many patients with this level of blood pressure elevation require careful medical supervision and therefore reliance on a stand-alone smartphone app may not be prudent. We also used home blood pressure monitors to evaluate our study outcomes, and these results were not independently verified for pragmatic reasons and to avoid the potential cointervention that would likely result from obtaining such external validation. Although patients were instructed on how to perform these measurements following guidance from the US Preventive Services Task Force, an organization that also endorses home blood pressure readings as a valid alternative to office-based assessments, 18 any inaccuracies in these measurements would bias our results to the null. Our results are also subject to the possibility of contamination. In the survey that participants completed at the end of follow-up, 17 individuals in the control group (8.4%) reported downloading the Medisafe app during the course of the trial, even though the name of the app being evaluated was not mentioned in the patient consent form. Conversely, as many as 10% of individuals in the intervention group did not launch the app and thus could not have benefited from it. Because we followed intention-to-treat principles, both of these factors would bias our results to the null. The intervention lasted for 12 weeks; therefore, we will be unable to determine the effect of the smartphone app on longer-term outcomes, including stroke or myocardial infarction. Finally, we tested a single app, Medisafe, and our results may not generalize to other smartphone-based interventions.
Conclusions
The availability of smartphone health apps has expanded quickly, with a recent study showing 160 medication adherence-specific health apps. 40 However, there has been a lack of rigorous evaluation to date, with most studies relying on self-report and not including a clinically important outcome. 7, 41 The MedISAFE-BP trial is, to our knowledge, the first randomized clinical trial reporting the effect of a stand-alone mHealth platform to increase medication adherence and improve blood pressure control. We found significant improvement in medication adherence, but no difference in systolic blood pressure between the intervention and control groups. the results of a study using a mobile health (mHealth) tool, called Medisafe, a highly rated smartphone app for medication management, which allows patients to track medication intake and home BP readings. In a relatively large, 3-month study, the authors demonstrated that patients with uncontrolled hypertension, randomized to using Medisafe, did not result in improved BP control compared with the control group. However, they did show a small, statistically significant, but clinically unimportant, improvement in medication adherence, measured by the 8-item Morisky Medication Adherence Scale. The study is a valuable addition to the growing body of literature assessing the role of mHealth technology in the health care sector; however, the results are disappointing for those of us who advocate for ongoing incorporation of mHealth strategies into current care. Historically, interventions that significantly improved BP control involved using nurses or pharmacists with the authority to prescribe or alter antihypertensive treatment. 
Introduction 31
Hypertension is a major factor in health issues such as stroke, heart disease, and kidney disease. 32
Worldwide there are 9.4 million deaths each year that can be attributed to hypertension and its effects 33 through cardiovascular disease (1). It has been estimated that annual medical expenditures of $46 billion 34 can be attributed to hypertension in the United States (2). Medications exist for the treatment of 35 hypertension and can prevent the harmful effects of elevated blood pressure and its associated morbidities 36 and mortalities, but medication adherence is a known barrier to effective treatment (3-5). 37
The rapid adoption of smartphone technologies (6) makes this an attractive avenue to influence 38 health practices, primarily medication adherence and subsequent blood pressure control. Smartphone 39 applications can deliver reminders about medication administration to encourage the proper timing and 40 adherence to prescriptions, provide education about healthy behaviors in life, be a means for loved-ones 41 to check in, create a network of patients to form a support system through social media, and monitor 42 biometric measurements. 43
Previous studies have examined the impact on hypertension of a smartphone application paired 44 with an on-call medical professional (1) or the effect of tele-monitoring (17, 19, 20) and found 45 improvements in blood pressure. Other smartphone-based interventions have been performed in people 46 with elevated cardiovascular risk, but have focused on text messages that are semi-personalized to the 47 patient (18). The impact of a stand-alone smartphone application on blood pressure has not been tested in 48 a rigorous manner, especially with regards to clinically meaningful outcomes of hypertension control. 49
Medisafe was developed to address non-adherence, and provide alerts to patients when it is time to take 50 their medications. Other features include the ability to allow a "Medfriend" to check in if a medication is 51 not taken, weekly reports of medication adherence, and monitoring of biometric measurements (either 52 directly into the application, or through synchronization with the smartphone's health applications). 53
Objectives and Overall Study Design 55
The Medication adherence Improvement Support App For Engagement -Blood Pressure 56 (MEDISAFE-BP) trial is a prospective, intent-to-treat randomized control trial that aims to evaluate the 57 impact of the Medisafe smart application on blood pressure control and self-reported medication 58 adherence for patients with uncontrolled blood pressure. 59
Patient Eligibility 61
Inclusion ≥ 18 and ≤ 75 years of age 
Subject Recruitment and Randomization 63
Recruitment will be conducted by Evidation Health, which uses an online strategy to virtually 64 announce, recruit, verify eligibility and enroll participants in clinical studies. Subjects will be recruited 65 through various digital platforms such as online patient communities, social media, pertinent mobile 66 applications, and targeted advertisements. As shown in Figure 1 , potential study subjects will be 67 evaluated for inclusion and exclusion criteria, will give informed consent, complete the baseline 68 assessment, and then be sent a Bluetooth-enabled home blood pressure cuff to verify that they have 69 uncontrolled blood pressure (systolic blood pressure ≥ 140 mmHg but overall blood pressure ≤ 180/120 70 mmHg). Patients will be provided with a study overview and blood pressure measurement guide that will 71 outline how to set up the monitor and take an accurate measurement, as well as the standard insert for 72 how to use the home monitor and its associated smartphone application. Blood pressure readings will be 73 electronically transmitted to Evidation Health via an Application Program Interface (API) with the blood 74 pressure monitor manufacturer. If patients are unable to activate the smartphone application associated 75 with the blood pressure monitor, they may submit their blood pressure readings by taking a time-stamped 76 photo of the blood pressure monitor display. Blood pressure will be calculated as the average of two 77 measurements that are taken five minutes apart, which is in accordance with previous literature (14) . 78
Once their blood pressure readings have been confirmed as being elevated, patients will undergo 79 randomization in a 1:1 ratio to intervention or control using simple randomization through a random 80 number generated at the time of study enrollment. 81
82
Informed Consent 83
Informed consent will be attained from subjects prior to enrollment using an eConsent process. 84
Patients will be told that a study is being conducted for evaluation of blood pressure, and focused on 85 strategies to optimize treatment using technology. They will also be informed of how their personal 86 5 information will be secured and that all analysis will be conducted on de-identified data. Because 87
Medisafe is a free application and notification may lead to use of this technology in the control arm, 88 patients will not be told about Medisafe before randomization. After randomization patients in the 89 intervention arm will be provided with information and instructions to download Medisafe. During the 90 informed consent process, there will be a contact form as well as a phone number and email available to 91 patients for any questions or to withdraw from the study. 92
93
Study Procedures 94
Prior to randomization, patients will be asked to complete a baseline assessment. This will 95 consist of baseline demographics including cardiovascular comorbidities, use of cigarettes, and education 96 level (15). The Morisky 8-item adherence scale will also be collected, which has been validated to 97 accurately capture anti-hypertensive medication adherence by self-report (8). Baseline hypertension 98 knowledge will also be assessed in accordance with Oliveira et. al (16). Subjects will also be asked to 99 complete the Consumer Health Activation Index (CHAI) as a marker for patient activation, as developed 100
by Wolf et al. Blood pressure monitors will then be mailed after the patients complete the baseline 101
assessment. 102
Patients assigned to the intervention arm will be emailed with instructions to download the 103 Medisafe application. Through an integration with Medisafe, Evidation Health will confirm that the 104 application has been downloaded and launched at least once within two days from randomization. 105
Patients who do not download and launch the application at least once within two days will be contacted 106 by email two more times and provided the instructions for download until they launch the application. If 107 they still do not launch the application, they will be contacted twice via telephone, then one final time by 108 email. If after three reminder e-mails and two phone calls the participant still does not launch the6 application, they will not be contacted further about downloading the application, but they will remain in 110 the intent-to-treat analysis group. 111
Patients assigned to the control arm will not receive any intervention. 112
At two time points, four and eight weeks after randomization, all subjects assigned to intervention 113 and control will be e-mailed and asked to measure their blood pressure using the Bluetooth-enabled blood 114 pressure cuff and its associated smartphone application (all blood pressures will be done via two 115 measurements, taken at least five minutes apart, and averaged (7)). If there is no blood pressure 116 measurement received within 2 days after the intended upload date, there will be two reminder e-mails 117 sent until a blood pressure measurement is received. If there is still no blood pressure measurement 118 received, two phone calls will be made to the study participant, followed by one final email reminder. If 119 they are unable to be reached by three reminder e-mails and two phone calls, they will not be contacted 120 again for that blood pressure measurement, but will be contacted to obtain the next assessment (either 8-121 week blood pressure measurement or study exit assessment) and will remain in the intent-to-treat analysis 122
group. 123
At 12 weeks, all subjects will be asked to complete an exit questionnaire consisting of Morisky 8-124 item medication adherence scale (8), hypertension knowledge questionnaire (16), and a CHAI. They will 125 also be asked to take their final blood pressure measurement. The same protocol described above of three 126 reminder e-mails and two phone calls will be followed, with one additional reminder email (for a 127 sequence of 2 reminder emails, 2 phone calls, 2 reminder emails), should there be a delay in answering 128 the questionnaire or taking the blood pressure measurement. Subjects who do not complete the exit 129 questionnaire or take their final blood pressure measurement will be lost to follow-up. After completing 130 the study, subjects will be given the option to keep the blood pressure cuff or donate it to an organization 131 that recycles digital health and wellness products for underserved populations. 132 pressure cuff more often than the four readings required in the study. That data will also be transmitted to 134
Evidation Health via the API and stored in the study database. 135
Throughout the study, subject data including blood pressure measurements and survey data will 136 be reviewed to ensure data quality and consistency. Patients may be contacted by phone or email to 137 address suspicious or unusual data submissions. 138
All study subjects will be provided compensation for their time to participate in the study, staged 139 in four intervals throughout the study (i.e., after randomization, after submitting blood pressure 140 measurement at 4 and 8 weeks after enrollment respectively, and after completion of final blood pressure 141 measurement and exit questionnaire). Maximum total compensation per study subject will not exceed 142 $150. 143
Data Security and Confidentiality 145
All identifiable information about patients, their medical conditions, and other study data will be 146 secured by Evidation Health in accordance with all local and state laws, regulations and Human Subjects 147
Committee policies regarding collection and distribution of patient information. Evidation Health will use 148 a HIPAA compliant survey system to collect the participant information and consent. Participant 149 information received from smartphone applications will be transmitted using Transport Layer Security 150
(TLS). 151
Data will only be stored electronically. All PHI and PII will be stored only on a single secured 152 server in the Amazon EC2 cloud designed exclusively for this purpose. The server will be protected by 153 two-factor authentication (requiring a password and a code generated on a separate device that changes 154 every 60 seconds). All communication with the server will be encrypted using TLS. Only Evidation 155
rest. 157
De-identified data will be stored on a separate password-secured server with data at rest 158
encryption. Only Evidation Health's Head of Operations and Data Science and Data Engineering teams 159
have access to this server. Only de-identified data will be transferred to the Center for Healthcare 160
Delivery Science (C4HDS) at Brigham Women's Hospital. Questionnaire data and other de-identified 161 data will only be linked to PHI and PII through a unique study-generated identifier. This identifier will be 162 generated via a secure cryptographic hash that cannot be reverse-engineered. 163
164
Outcomes 165
The study's co-primary outcomes will be a change in systolic blood pressure from randomization 166 to three months later and self-reported medication adherence (see Table 1 ). The secondary outcome will 167 be change in number of subjects who have well controlled blood pressure (<140/90 mmHg). 168
169
Analytic Plan 170
The Center for Healthcare Delivery Science (C4HDS) at Brigham Women's Hospital will 171 conduct all analysis on de-identified data. We will report baseline patient characteristics and evaluate 172 differences in the two groups to identify any potentially unmatched covariates despite randomization. We 173 will plot changes in blood pressure over time. 174
Analyses will be performed by an intent-to-treat basis, where subjects will be analyzed in the 175 groups they are assigned to during randomization. We will use linear regression to assess the impact of 176
Medisafe on the study's 2 primary outcomes (change in systolic blood pressure and self-reported 177 adherence) between the two study groups, 3 months after randomization. Our primary models will adjust9 for unbalanced covariates between the two groups. Only the initial and 12-week blood pressure readings 179 will be included in the primary analysis. 180
In secondary analyses, we will determine the number of patients that had their hypertension 181 controlled (i.e., <140/90mmHg) during the study period in both arms, and calculate an odds ratio using 182 multivariate logistic regression in order to control for potentially unmatched baseline covariates. We will 183 also repeat our analyses with longitudinal modeling methods that incorporate blood pressure readings at 184 4, 8, and 12 weeks after randomization. If there are additional blood pressure readings from patients who 185 took their blood pressure more often than required, we will include this data in exploratory longitudinal 186 modeling analyses. 187
In supplemental analyses, we will evaluate whether the impact of Medisafe differed for subjects 188 who interacted with Medisafe frequently (defined as being in the upper median of use for the Medisafe 189 application based on frequency of user sessions during the study period) as compared to subjects who 190 interacted with Medisafe less frequently. We will perform this analysis by including categorical variables 191 for high and low use in our outcome model, whereby control subjects are indicating by null values for 192 both of these indicators. We will also evaluate effect modification by hypertension knowledge (16) 193 recorded at baseline. 194
195
Sample Size 196
With a change in systolic blood pressure of 5mmHg, which has previously been shown to be 197 clinically significant (12,13), a standard deviation of 17mmHg, a power of 80%, and an alpha of 0.05 198 there would need to be 312 patients enrolled. With allowance for 20% loss to follow-up, the study will 199 seek to enroll 390 patients total to have an 80% power with an alpha of 5%. With a standard deviation of 200 1.6 (8) and a sample size of 390 patients, we will be able to detect a 0.5 Morisky score difference between 201 the groups with a power of 87%. 202
Risks Associated with the Intervention 204
Since the intervention under investigation is not aimed at altering a patient's treatment, but rather 205 to promote adherence to treatments that they have already been prescribed, the risk will be minimal. 206
There is a possible risk of patients receiving escalating anti-hypertensive medications from their treatment 207 team due to non-adherence, and with the better adherence through Medisafe reminders there could be 208 medication induced hypotension. During the informed consent process and on the blood pressure 209 measurement guidance sheet there will be recommendations to reach out to their treatment team if they 210 ever have a blood pressure > 180/120 mmHg or < 90/50 mmHg. The informed consent will also clearly 211 state that no component of the study, including the home blood pressure cuff use and study personnel, is a 212 replacement for care from a health care professional. 213
The likelihood that a study participant has a blood pressure reading > 180/120 mmHg or < 90/50 214 mmHg during the study is very low, since this is a low-risk patient population. Inclusion criteria is limited 215 to patients with stage I or II hypertension, and patients with an initial blood pressure reading > 180/120 216 mmHg will be excluded. Patients taking more than three anti-hypertensive medications will also be 217 excluded. Additionally, patients will be notified during the informed consent process that their blood 218 pressure readings will not be monitored by the research team, and that they should reach out to their 219 treatment team if their blood pressure is ever very high or very low. 220
Final protocol 221
Introduction 223 Hypertension is a major factor in health issues such as stroke, heart disease, and kidney disease. 224
Worldwide there are 9.4 million deaths each year that can be attributed to hypertension and its effects 225 through cardiovascular disease (1). It has been estimated that annual medical expenditures of $46 billion 226 can be attributed to hypertension in the United States (2). Medications exist for the treatment of 227 hypertension and can prevent the harmful effects of elevated blood pressure and its associated morbidities 228 and mortalities, but medication adherence is a known barrier to effective treatment (3) (4) (5) . 229
The rapid adoption of smartphone technologies (6) makes this an attractive avenue to influence 230 health practices, primarily medication adherence and subsequent blood pressure control. Smartphone 231 applications can deliver reminders about medication administration to encourage the proper timing and 232 adherence to prescriptions, provide education about healthy behaviors in life, be a means for loved-ones 233 to check in, create a network of patients to form a support system through social media, and monitor 234 biometric measurements. 235
Previous studies have examined the impact on hypertension of a smartphone application paired 236 with an on-call medical professional (1) or the effect of tele-monitoring (17, 19, 20) and found 237 improvements in blood pressure. Other smartphone-based interventions have been performed in people 238 with elevated cardiovascular risk, but have focused on text messages that are semi-personalized to the 239 patient (18). The impact of a stand-alone smartphone application on blood pressure has not been tested in 240 a rigorous manner, especially with regards to clinically meaningful outcomes of hypertension control. 241
Medisafe was developed to address non-adherence, and provide alerts to patients when it is time to take 242 their medications. Other features include the ability to allow a "Medfriend" to check in if a medication is 243 not taken, weekly reports of medication adherence, and monitoring of biometric measurements (either 244 directly into the application, or through synchronization with the smartphone's health applications).
246
Objectives and Overall Study Design 247
The Medication adherence Improvement Support App For Engagement -Blood Pressure 248 (MEDISAFE-BP) trial is a prospective, intent-to-treat randomized control trial that aims to evaluate the 249 impact of the Medisafe smart application on blood pressure control and self-reported medication 250 adherence for patients with uncontrolled blood pressure. Recruitment will be conducted by Evidation Health, which uses an online strategy to virtually 256 announce, recruit, verify eligibility and enroll participants in clinical studies. Subjects will be recruited 257 through various digital platforms such as online patient communities, social media, pertinent mobile 258 applications, and targeted advertisements. As shown in Figure 1 , potential study subjects will be 259 evaluated for inclusion and exclusion criteria, will give informed consent, complete the baseline 260 assessment, and then be sent a Bluetooth-enabled home blood pressure cuff to verify that they have 261 uncontrolled blood pressure (≥ 140/90 mmHg but ≤ 180/120 mmHg). Patients will be provided with a 262 study overview and blood pressure measurement guide that will outline how to take an accurate 263 measurement, as well as the standard insert for how to use the home monitor and its associated 264 smartphone application. Blood pressure readings will be electronically transmitted to Evidation Health via 265 an Application Program Interface (API) with the blood pressure monitor manufacturer. If patients are 266 unable to activate the smartphone application associated with the blood pressure monitor, they may 267 submit their blood pressure readings by taking a time-stamped photo of the blood pressure monitor 268 display. Blood pressure will be calculated as the average of two measurements that are taken five minutes 269 apart, which is in accordance with previous literature (14). Once their blood pressure readings have been 270 confirmed as being elevated, patients will undergo randomization in a 1:1 ratio to intervention or control 271 using simple randomization through a random number generated at the time of study enrollment. 272 14 Informed consent will be attained from subjects prior to enrollment using an eConsent process. 275
Patients will be told that a study is being conducted for evaluation of blood pressure, and focused on 276 strategies to optimize treatment using technology. They will also be informed of how their personal 277 information will be secured and that all analysis will be conducted on de-identified data. Because 278
Medisafe is a free application and notification may lead to use of this technology in the control arm, 279 patients will not be told about Medisafe before randomization. After randomization patients in the 280 intervention arm will be provided with information and instructions to download Medisafe. During the 281 informed consent process, there will be a contact form as well as a phone number and email available to 282 patients for any questions or to withdraw from the study. 283
284
Study Procedures 285
Prior to randomization, patients will be asked to complete a baseline assessment. This will 286 consist of baseline demographics including cardiovascular comorbidities, use of cigarettes, and education 287 level (15). The Morisky 8-item adherence scale will also be collected, which has been validated to 288 accurately capture anti-hypertensive medication adherence by self-report (8). Baseline hypertension 289 knowledge will also be assessed in accordance with Oliveira et. al (16) . Subjects will also be asked to 290 complete the Consumer Health Activation Index (CHAI) as a marker for patient activation, as developed 291 by Wolf et al. Blood pressure monitors will then be mailed after the patients complete the baseline 292
assessment. 293
Patients assigned to the intervention arm will be emailed with instructions to download the 294 Medisafe application. Through an integration with Medisafe, Evidation Health will confirm that the 295 application has been downloaded and launched at least once within two days from randomization. 296
Patients who do not download and launch the application at least once within two days will be contacted 297 by email two more times and provided the instructions for download until they launch the application. If 298 they still do not launch the application, they will be contacted twice via telephone, then one final time by 299 email. If after three reminder e-mails and two phone calls the participant still does not launch the 300 application, they will not be contacted further about downloading the application, but they will remain in 301 the intent-to-treat analysis group. 302
Patients assigned to the control arm will not receive any intervention. 303
At two time points, four and eight weeks after randomization, all subjects assigned to intervention 304 and control will be e-mailed and asked to measure their blood pressure using the Bluetooth-enabled blood 305 pressure cuff and its associated smartphone application (all blood pressures will be done via two 306 measurements, taken at least five minutes apart, and averaged (7)). If there is no blood pressure 307 measurement received within 2 days after the intended upload date, there will be two reminder e-mails 308 sent until a blood pressure measurement is received. If there is still no blood pressure measurement 309 received, two phone calls will be made to the study participant, followed by one final email reminder. If 310 they are unable to be reached by three reminder e-mails and two phone calls, they will not be contacted 311 again for that blood pressure measurement, but will be contacted to obtain the next assessment (either 8-312 week blood pressure measurement or study exit assessment) and will remain in the intent-to-treat analysis 313
group. 314
At 12 weeks, all subjects will be asked to complete an exit questionnaire consisting of Morisky 8-315 item medication adherence scale (8), hypertension knowledge questionnaire (16), and a CHAI. They will 316 also be asked to take their final blood pressure measurement. The same protocol described above of three 317 reminder e-mails and two phone calls will be followed, with one additional reminder email (for a 318 sequence of 2 reminder emails, 2 phone calls, 2 reminder emails), should there be a delay in answering 319 the questionnaire or taking the blood pressure measurement. Subjects who do not complete the exit 320 questionnaire or take their final blood pressure measurement will be lost to follow-up. After completing 321 the study, subjects will be given the option to keep the blood pressure cuff or donate it to an organization 322 that recycles digital health and wellness products for underserved populations. 323 pressure cuff more often than the four readings required in the study. That data will also be transmitted to 325
Evidation Health via the API and stored in the study database. 326
Throughout the study, subject data including blood pressure measurements and survey data will 327 be reviewed to ensure data quality and consistency. Patients may be contacted by phone or email to 328 address suspicious or unusual data submissions. 329
All study subjects will be provided compensation for their time to participate in the study, staged 330 in four intervals throughout the study (i.e., after randomization, after submitting blood pressure 331 measurement at 4 and 8 weeks after enrollment respectively, and after completion of final blood pressure 332 measurement and exit questionnaire). Maximum total compensation per study subject will not exceed 333 $150. 334
335
Data Security and Confidentiality 336
All identifiable information about patients, their medical conditions, and other study data will be 337 secured by Evidation Health in accordance with all local and state laws, regulations and Human Subjects 338
Committee policies regarding collection and distribution of patient information. Evidation Health will use 339 a HIPAA compliant survey system to collect the participant information and consent. Participant 340 information received from smartphone applications will be transmitted using Transport Layer Security 341
(TLS). 342
Data will only be stored electronically. All PHI and PII will be stored only on a single secured 343 server in the Amazon EC2 cloud designed exclusively for this purpose. The server will be protected by 344 two-factor authentication (requiring a password and a code generated on a separate device that changes 345 every 60 seconds). All communication with the server will be encrypted using TLS. Only Evidation
rest. 348
De-identified data will be stored on a separate password-secured server with data at rest 349 encryption. Only Evidation Health's Head of Operations and Data Science and Data Engineering teams 350 have access to this server. Only de-identified data will be transferred to the Center for Healthcare 351
Delivery Science (C4HDS) at Brigham Women's Hospital. Questionnaire data and other de-identified 352 data will only be linked to PHI and PII through a unique study-generated identifier. This identifier will be 353 generated via a secure cryptographic hash that cannot be reverse-engineered. 354
355
Outcomes 356
The study's co-primary outcomes will be a change in blood pressure from randomization to three 357 months later and self-reported medication adherence (see Table 1 ). The secondary outcome will be 358 change in number of subjects who have well controlled blood pressure (<140/90 mmHg). 359
360
Analytic Plan 361
The Center for Healthcare Delivery Science (C4HDS) at Brigham Women's Hospital will 362 conduct all analysis on de-identified data. Analyses will be performed by an intent-to-treat basis, where 363 subjects will be analyzed in the groups they are assigned to during randomization. 364
We will begin by comparing the baseline patient characteristics in each of the arms using t-tests, 365 chi-square tests or their non-parametric analogues, as appropriate. We will evaluate for rates of missing 366 data between the two study arms to ensure that it is non-differential. 367
We will use linear regression to assess the impact of Medisafe on the study's 2 primary outcomes 368 (change in blood pressure and self-reported adherence) between the two study groups. Our null 369
Sample Size 398
With a change in blood pressure of 5mmHg, which has previously been shown to be clinically 399 significant (12,13), a standard deviation of 167mmHg, a power of 80%, and an alpha of 0.05 there would 400 need to be 312 patients enrolled. With allowance for 20% loss to follow-up, the study will seek to enroll 401 390 patients total to have an 80% power with an alpha of 5%. With a standard deviation of 1.6 (8) and a 402 sample size of 390 patients, we will be able to detect a 0.5 Morisky score difference between the groups 403 with a power of 87%. 404 
Analytic Plan 430
The Center for Healthcare Delivery Science (C4HDS) at Brigham Women's Hospital will 431 conduct all analysis on de-identified data. We will report baseline patient characteristics and evaluate 432 differences in the two groups to identify any potentially unmatched covariates despite randomization. We 433 will plot changes in blood pressure over time. 434
Analyses will be performed by an intent-to-treat basis, where subjects will be analyzed in the 435 groups they are assigned to during randomization. We will use linear regression to assess the impact of 436
Medisafe on the study's 2 primary outcomes (change in systolic blood pressure and self-reported 437 adherence) between the two study groups, 3 months after randomization. Our primary models will adjust 438 for unbalanced covariates between the two groups. Only the initial and 12-week blood pressure readings 439 will be included in the primary analysis. 440
In secondary analyses, we will determine the number of patients that had their hypertension 441 controlled (i.e., <140/90mmHg) during the study period in both arms, and calculate an odds ratio using 442 multivariate logistic regression in order to control for potentially unmatched baseline covariates. We will 443 also repeat our analyses with longitudinal modeling methods that incorporate blood pressure readings at 444 4, 8, and 12 weeks after randomization. If there are additional blood pressure readings from patients who 445 took their blood pressure more often than required, we will include this data in exploratory longitudinal 446 modeling analyses. 447
In supplemental analyses, we will evaluate whether the impact of Medisafe differed for subjects 448 who interacted with Medisafe frequently (defined as being in the upper median of use for the Medisafe 449 application based on frequency of user sessions during the study period) as compared to subjects who 450 interacted with Medisafe less frequently. We will perform this analysis by including categorical variables 451 for high and low use in our outcome model, whereby control subjects are indicating by null values for 452
Sample Size 502
With a change in blood pressure of 5mmHg, which has previously been shown to be clinically 503 significant (12,13), a standard deviation of 176mmHg, a power of 80%, and an alpha of 0.05 there would 504 need to be 312 patients enrolled. With allowance for 20% loss to follow-up, the study will seek to enroll 505 390 patients total to have an 80% power with an alpha of 5%. With a standard deviation of 1.6 (8) and a 506 sample size of 390 patients, we will be able to detect a 0.5 Morisky score difference between the groups 507 with a power of 87%. 
